Cargando…

PB1968: IMPACTS ON OUTCOMES AND A PREDICTIVE MODEL OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL NILOTINIB-THERAPY

Detalles Bibliográficos
Autores principales:	LI, Ziyu, Jiang, Qian, Zhang, Xiaoshuai, Zhang, Yanli, Xu, Na, Zhu, Huanling, Lin, Hai, LI, Weiming, Du, Xin, Liang, Rong, LI, Fei, Chen, Chunyan, Liu, Bingcheng, Wang, Xiaodong, Yang, Lijie, Liu, Zhenfang, Pang, Liping, Liu, Zhuogang, Sun, Xiuli, Bai, Yanliang, Meng, LI, Chen, Suning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429811/ http://dx.doi.org/10.1097/01.HS9.0000974688.76077.3c

Ejemplares similares

PB1971: A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF HS-10382 (TERN-70) IN CHRONIC MYELOID LEUKEMIA PATIENTS
por: LI, Weiming, et al.
Publicado: (2023)

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
por: Chen, Yilin, et al.
Publicado: (2023)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

PB1969: PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND CORONAVIRUS DISEASE 2019 IN THE OMICRON ERA
por: Qi, Feiyang, et al.
Publicado: (2023)

PB1724: NILOTINIB PLUS CHEMOTHERAPY IN PEDIATRICS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
por: LI, Yanming, et al.
Publicado: (2023)

PB1960: SARS-COV-2 OMICRON VARIANT INFECTION AND COVID-19 IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA IN CHINA
por: Cheng, Fang, et al.
Publicado: (2023)

PB2621: TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH HETROMBOPAG—A SINGLE-CENTER RETROSPECTIVE, OBSERVATIONAL STUDY
por: Zhou, Hu, et al.
Publicado: (2023)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB1968: EPIGENETIC AND GENETIC INVESTIGATION OF SOCS-1 GENE IN PATIENTS WITH MULTIPLE MYELOMA
por: Serin, I., et al.
Publicado: (2022)

Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China
por: Yang, Yunfan, et al.
Publicado: (2022)

PB2604: THE ROLE OF THE GUT MICROBIOTA IN MEDIATING BONE MARROW MESENCHYMAL STEM CELLS DEFICIENCY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN PREGNANCY
por: Chen, Qi, et al.
Publicado: (2023)

PB2308: QUALITY OF LIFE AND CLINICAL OUTCOMES IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ROMIPLOSTIM IN A REAL-WORLD SETTING
por: Ionova, T., et al.
Publicado: (2022)

Epidemiology and Ecology of Severe Fever With Thrombocytopenia Syndrome in China, 2010‒2018
por: Miao, Dong, et al.
Publicado: (2020)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
por: Jones, C., et al.
Publicado: (2022)

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2023)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services
por: Bao, Mei, et al.
Publicado: (2021)

PB1951: PROGNOSTIC SIGNIFICANCE OF CLINICAL INDICATORS RELATED TO AMINO ACID METABOLISM IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Liu, Ming, et al.
Publicado: (2023)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

PB2607: OBESITY IMPAIRS RESPONSE TO FIRST-LINE HIGH-DOSE DEXAMETHASONE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.
por: Feng, Gege, et al.
Publicado: (2023)

PB1954: PROGNOSTIC ANALYSIS OF GENE MUTATIONS ON TIME-TO-FIRST TREATMEN IN 93 NEWLY DIAGNOSED CHRONIC LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Xiang, Xixi, et al.
Publicado: (2023)

PB2685: QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
por: Bhat, Vivek, et al.
Publicado: (2023)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
por: Yang, Shenmiao, et al.
Publicado: (2023)

PB1946: NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV-INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA
por: Shang, Chunyu, et al.
Publicado: (2023)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

Juvenile Hormone Studies in Drosophila melanogaster
por: Zhang, Xiaoshuai, et al.
Publicado: (2022)

PB2301: PEDIATRIC IMMUNE THROMBOCYTOPENIA; A GLANCE AT PATIENTS AND CURRENT THERAPEUTIC CHALLENGES
por: Al-Jadiry, M., et al.
Publicado: (2022)

PB2066: SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED AMEGAKARYOCYTIC THROMBOCYTOPENIA AND SUBSEQUENT APLASTIC ANEMIA
por: Seong, Gyuhee, et al.
Publicado: (2023)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

PB1931: LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL-IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Gao, Rui, et al.
Publicado: (2023)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jna9g2or51eg2likui3akdd4o0